Each year, 15 million people suffer a stroke, and nearly half are left with lasting mobility problems. While walking is key to independence and quality of life, most survivors never recover from it, not because recovery is impossible, but because the rehabilitation system fails them. In the U.S., only 31% of patients receive adequate outpatient rehab. Hospital therapy is short and costly, and once home, patients face a steep drop in care: not enough time, intensity, or support. The result is often permanent disability, long-term dependence, and a major burden on families and healthcare systems.
Autonomyo brings high-intensity rehab to every home
Autonomyo is the first company to make robot-assisted walking rehabilitation available both in clinics and at home: safely, affordably, and with clinical quality.
At the heart of the solution are two complementary devices:
- NeuroXO: a smart wearable exoskeleton that adapts in real time to the patient’s capabilities. It enables natural, guided walking with just the right amount of assistance. No more rigid, pre-programmed motions, NeuroXO listens to the patient and responds.
- Skywalk: a mechanical bodyweight support frame that ensures verticality and fall safety. At EUR 9,000 retail, it is 4x more affordable than current solutions and fully compatible with NeuroXO. It can be used in clinics or at home for early mobilization or paired training.
Together, they deliver the first home-suitable robotic rehab platform, designed for stroke, MS, Parkinson’s, neuromuscular disorders, and the elderly. It’s a complete, scalable solution that evolves with the patient, from hospital bed to full recovery.
Clinically proven, medically trusted
Autonomyo’s system has already completed early clinical trials at CHUV and the Institution de Lavigny (Switzerland), with 22 patients suffering from lower-limb impairments (primarily post-stroke). Results show:
- 100% patient-reported safety and usability
- 0 safety incidents
- 2x more training intensity vs conventional therapy
Therapists reported that patients trained longer, more effectively, and with greater engagement, making a clear case for better outcomes.
A global market waiting to be served
The rehabilitation robotics market is entering a period of rapid growth, driven by the increasing prevalence of neurological and musculoskeletal disorders, advances in robotics, sensors, and AI, in addition to the systemic push toward home-based and personalized care.
Autonomyo’s target markets include Europe, the US, and India, where demographic aging, stroke prevalence, and healthcare system strain create strong demand for cost-effective solutions that reduce long-term disability.
This round: bridging to market
Autonomyo is raising €550,000 as the first tranche of its €2.15M seed round. This bridge round enables the market launch of Skywalk, generating first revenues, while also supporting the completion of clinical validation, final CE and FDA certification steps, and preparing market entry operations for NeuroXO.
The round is backed by founders and experienced angel investors (€159,600 already secured), with institutional investors expected in later tranches. Structured across 24 months, the full seed round paves the way for industrialization, regulatory approvals, and commercialization.
In parallel, autonomyo will leverage significant non-dilutive funding instruments:
- Innosuisse SIP Project – up to €2.05M
- Eurostars Project – up to €1.5M
- FIT Growth Loan – up to €500K
With this the seed financing achieves a strong leverage effect—every euro of dilutive capital unlocks multiple euros of support.
Furthermore there are already €1.25M committed investment with LOIs for dilutive funding in the seed round that will close Q1 2026.
The company targets an exit by 2030, with a projected valuation of €60–100M and 10x+ ROI for investors.
A breakthrough for patients and for investors
Autonomyo is not just improving rehab, it’s rebuilding lives after neurological injury. By bringing clinically validated, robot-assisted therapy into the home, it has the potential to reduce post-stroke disability by 50%.
Join us in closing the care gap for millions of stroke and neuro patients. Invest in Autonomyo today, and help create a world where recovery doesn’t stop when the hospital stay ends.
